Balto Pharmaceuticals, Inc.
June 22, 2026
Theater 2
Type: Company Presentation
Focus Area:
Oncology
Balto is both a platform and a pipeline biotech focused on the discovery of small molecule inhibitors targeting cooperative stability of protein-protein interactions (PPIs) in protein complexes that drive cancer and other diseases. These small molecule drug candidates disrupt PPIs and elicit degradation of the interacting proteins, which are termed DISGRADER™ inhibitors. Unlike PROTACs (700-1200 Da) in induced-proximity, molecular weights of DISGRADER™ inhibitors are under 400 Da, hence eliminating developmental constraints of the larger PROTACs. Using its proprietary DisRuPPT platform, Balto has discovered first-in-class small molecule PPI inhibitors targeting a pan-cancer multi-protein transcription complex. These pan cancer PPI disruptors inhibit tumor growth by inducing massive tumor infiltrating lymphocytes in otherwise immunologically unresponsive tumors in mouse models, thereby turning cold tumors hot.
Company HQ City:
South Pasadena
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
August 2015
Lead Product in Development:
BP36 optimization should be completed in the summer of 2026.
The construction of the technology platforms have completed.
CEO
Wilson Xu
Development Phase of Lead Product
Pre-Clinical
Number of Unlicensed Products Looking for Licensing
Three technology platforms and two assets
When you expect your next catalyst update?
Lead optimization should be completed around the summer of 2026. PCC should be nominated towards the end of 2026.
What is your next catalyst (value inflection) update?
Lead optimization for the assets should be completed in the summer of 2026; The construction of the technology platforms have completed.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}